(NASDAQ: GLUE) Monte Rosa Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Monte Rosa Therapeutics's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast GLUE's revenue for 2024 to be $863,653,137, with the lowest GLUE revenue forecast at $836,068,397, and the highest GLUE revenue forecast at $891,237,877. On average, 2 Wall Street analysts forecast GLUE's revenue for 2025 to be $863,653,137, with the lowest GLUE revenue forecast at $836,068,397, and the highest GLUE revenue forecast at $891,237,877.
In 2026, GLUE is forecast to generate $780,648,146 in revenue, with the lowest revenue forecast at $725,227,896 and the highest revenue forecast at $836,068,397.